Monitor for shareholder approval and regulatory clearances, as the transaction is expected to close in early 2027. The premium offered suggests strong confidence in Organon's value, making it an attractive near-term opportunity for investors.
Price Chart
Executive Summary
Organon & Co. has entered into a definitive merger agreement with Sun Pharmaceutical, under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in cash, representing a 103% premium. The deal values Organon at an enterprise value of $11.75 billion and is subject to regulatory approvals and shareholder vote. Concurrently, Joseph Morrissey was appointed permanent CEO and Carrie Cox as Executive Chair on a non-interim basis.
Key Financial Metrics
Key Facts
- Sun Pharmaceutical will acquire Organon for $14.00 per share in cash, a 103% premium to the unaffected trading price.
- The transaction values Organon at an enterprise value of $11.75 billion.
- The merger is subject to regulatory approvals and shareholder vote.
- Joseph Morrissey was appointed permanent CEO of Organon.
- Carrie Cox was appointed Executive Chair on a non-interim basis.
Financial Impact
Enterprise value of $11.75 billion with $14.00 per share cash consideration
Risk Factors
- Failure to obtain regulatory approvals
- Failure to secure shareholder vote
- Potential termination fee of $120 million if deal is terminated under certain circumstances
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-178729 |
| Document: 0001193125-26-178729-index-headers.html | 0001193125-26-178729 |
| Document: 0001193125-26-178729-index.html | 0001193125-26-178729 |
| Document: 0001193125-26-178729.txt | 0001193125-26-178729 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | Institutional Cluster | $13.68 | awaiting T+60 | — | $13.74 (−0.44%) |
Jul 31, 2026 12w ago | 8-K | $13.55 $13.74 | ▼ −1.40% | ▲ +1.05% | $13.74 (−1.40%) |
Jul 17, 2026 14w ago | 8-K | $13.49 $13.77 | ▲ +2.08% | ▼ −2.76% | $13.74 (+1.85%) |
Jun 17, 2026 18w ago | DEFM14A | $13.42 $13.64 | ▲ +1.64% | ▼ −1.51% | $13.74 (+2.38%) |
Jun 11, 2026 19w ago | DEFA14A | $13.45 $13.78 | ▲ +2.45% | ▼ −1.94% | $13.74 (+2.16%) |
Jun 1, 2026 21w ago | PREM14A | $13.37 $13.75 | ▲ +2.84% | ▲ +1.87% | $13.74 (+2.81%) |
Apr 30, 2026 25w ago | DEFA14A | $13.25 $13.52 | ▲ +2.08% | ▼ −0.74% | $13.74 (+3.74%) |
Apr 30, 2026 25w ago | 8-K | $13.25 $13.52 | ▼ −2.08% | ▲ +0.74% | $13.74 (−3.74%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers